Detective Work I have not heard back from the company yet. Let me share with everyone some things I found and you can tell me what they mean to you. There are some mis-understandings floating around.
The replay of the 3Q2012 earnings conference call can be found at [https://podcast.newswire.ca/media/diagnocure20120906.mp3]. It worked on Monday but is not working for me tonight. Also make sure when you click on it that Stockhouse sends you to exactly that website as I typed it. There seems to be a bug in Stockhouse (sometimes) if you click on the live link. It is all in English except for the welcome by the Newswire Operator. It is quite short.
What is going on at Signal Genetics? On Friday March 23 2012, Washington Business Journal reported that "Signal Genetics LLC, a cancer diagnostics company helmed by former Digene Corp and Innovative Biosensors Inc executive Joe Hernandez, is shifting its laboratory functions and the bulk of its staff to Rockville. The company has signed a lease for roughly 7,500 square feet of lab space at 1330 Piccard Drive, where it will consolidate operations from sites in Arkansas and Pennsylvania, said Hernandez, the company's CEO. He hopes to have 20 to 30 employees working out of the space by the end of the year, many of them new hires. Signal Genetics' headquarters will remain on Madison Avenue in New York, where Hernandez will split his time." (Rockville is a suburb of Washington DC. A lot of military technology contractors are located there, to be close to the Pentagon.)
Then on April 6 2012, Washington Business Journal reported "Well-known bio entrepreneur Joe Hernandez is resigning as president and CEO of Signal Genetics LLC. ... Hernandez confirmed he is stepping down, though he declined to offer any other details. ... Signal Genetics declined to comment."
Signal Genetics is a private company. LinkedIn shows John Shaughnessy reporting to be owner of the company. He is located in Little Rock, Arkansas. The Signal Genetics website (tonight) shows two lab locations: Arkansas and Pennsylvania. But they only show skin cancer testing, no colorectal cancer testing. There is no mention of the Rockville Maryland lab. If anyone wants to try calling them, there are pictures of the labs and phone numbers at [www.signalgenetics.com/aboutus_contacts.html]
Tonight, I found Joe Hernandez working at [www.proliastechnologies.com] which is a startup doing biomarker tests. He is listed as Chairman and CEO. His LinkedIn page does not show an employer (tonight).
I also found a report on Diagnocure by Zacks Equity Research on Yahoo! Finance. It was published Friday Sep 7, 2012. He said he listened to the call and as a result, lowered his model parameters for PCA3 revenue. "Given the recent disappointing sales, we made downward revisions to this line item in our model - mostly effecting the near-term." His new target price is $1.80 per share (still outperform). But he did not mention that Diagnocure reports royalty revenue on a cash basis (when received) and that, for some reason, Gen-Probe is now 6 months behind in reporting sales of PCA3 and paying royalty. So I think he missed that comment by Dr Fradet. (I have never seen this in writing in Diagnocure's statutory filings. I have an itch to file a complaint with the QSC, but its a small company and they have their hands full right now. I will hold off.) Ready2Go, maybe Zachs will listen to you if you explain the revenue lag to him, one American to another. As I said, nobody is listening very well and the company is not explaining it clearly, even though Dr Fradet's English is flawless.
So ... what does all this mean to you? There are about 5 people posting and 50 more people lurking. Time for everyone to help with the detective work because the company will not be saying anything for legal reasons until they have a final resolution. And that is a good thing. I agree 100% with that approach.